Onkologie, Hämatologie - Daten und Informationen
SitemapSitemap  


Literaturreferenzen des Artikels "Mammakarzinom"

Autor/en: A.C. Regierer, K. Possinger
Letzte Änderung: 17.10.2005
  • [No authors listed].
    A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia.
    J Clin Oncol 1986;4:186-193. PM:2868074
    [Medline]


  • Akrivakis K, Schmid P, Flath B et al.
    Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study. Anticancer drugs 1999;10:525-531. PM:10885899
    [Medline]


  • Armstrong K, Eisen A, Weber B.
    Assessing the risk of breast cancer.
    N Engl J Med 2000;342:564-571. PM:10684916
    [Medline]


  • Bardou VJ, Arpino G, Elledge RM, et al.
    Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.
    J Clin Oncol 2003;21:1973-1979. PM:12743151
    [Medline]


  • Bardou VJ, Gebauer G, Fehm T, Merkle E, et al.
    Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term followup.
    J Clin Oncol 2001;19:3669-3674. PM:11504748
    [Medline]


  • Bartelink H.
    Commentary on the paper "A preliminary report of intraoperative radiotherapy (IORT) in limited-stage breast cancers that are conservatively treated". A critical review of an innovative approach.
    Eur J Cancer 2001;37:2143-2146. PM:11677099
    [Medline]


  • Bässler R, Böcker W, Hermanek P, et al.
    [Current status of grading in breast cancer].
    Pathologe 1992;13:130-134. PM:1620676
    [Medline]


  • Batist G, Ramakrishnan G, Rao CS, et al.
    Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
    J Clin Oncol 2001;19:1444-1454. PM:11230490
    [Medline]


  • Baum M, Budzar AU, Cuzick J, et al.
    Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
    Lancet 2002;359:2131-2139. PM:14584060
    [Medline]


  • Beral V, Million Women Study Collaborators.
    Breast cancer and hormone-replacement therapy in the Million Women Study.
    Lancer 2003;362:419-427. PM:12927427
    [Medline]


  • Boccardo F, Rubagotti A, Amoroso D, et al.
    Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study.
    J Clin Oncol 2001;19:4209-4215. PM:11709564
    [Medline]


  • Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C.
    Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up.
    N Engl J Med 1995;332:901-906. PM:7877646
    [Medline]


  • Brodie A.
    Aromatase inhibitors in breast cancer.
    Trends Endocrinol Metab 2002;13:61-65. PM:11854020
    [Medline]


  • Cavalieri EL, Rogan EG.
    A unifying mechanism in the initation of cancer and other diseases by catechol quinones.
    Anm NY Acad Sei 2004;1028:247-257. PM:15650250
    [Medline]


  • Chan S.
    Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
    Oncology (Huntingt) 1997;11:19-24. PM:9364537
    [Medline]


  • Chia SKL, Speers C, Kang A, et al.
    The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer (MBC) in a population based cohort.
    Proc Am Soc Clin Oncol 2003;6 (abstr 22)


  • Citron ML, Berry DA, Cirrincione C, et al.
    Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of nodepositive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
    J Clin Oncol 2003;21:1431-1439. PM:12668651
    [Medline]


  • Cold S, Jensen NV, Brincker H, Rose C.
    The influence of chemotherapy on survival after recurrence in breast cancer - a popu-lation-based study of patients treated in the 1950s, 1960s and 1970s.
    Eur J Cancer 1993;29A:1146-1152. PM:8518025
    [Medline]


  • Colleoni M, Bonetti M, Coates AS, et al.
    Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group.
    J Clin Oncol 2000;18:584-590. PM:10653873
    [Medline]


  • Coombes RC, Hall E, Gibson LJ, et al.
    A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
    N Engl J Med 2004;350:1081-1092. PM:15014181
    [Medline]


  • Cresta S, Grasselli G, Martoni A, et al.
    A randomized phase II study of alternating (AA) vs sequential (SS) vs the combination (CC) of Doxorubicin (A) and Docetaxel (T) as 1st line CT in MBC Pts.
    Proc Am Soc Clin Oncol 2001;20:190. PM:14998845
    [Medline]


  • Cuzick J, Powles T, Veronesi U, et al.
    Overview of the main outcomes in breast-cancer prevention trials.
    Lancet 2003;361:296-300. PM:12559863
    [Medline]


  • Daudt A, Alberg AJ, Helzlsouer KJ.
    Epidemiology, prevention, and early detection of breast cancer.
    Curr Opin Oncol 1996;8:455-461. PM:8971464
    [Medline]


  • Del Mastro L, Venturini M, Lionetto R, et al.
    Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group.
    J Clin Oncol 2001;19:2213-2221. PM:11304774
    [Medline]


  • Diel IJ, Solomayer EF, Costa SD et al.
    Reduction in new metastases in breast cancer with adjuvant clodronate treatment.
    N Engl J Med 1998;339:357-363. PM:9691101
    [Medline]


  • Di Leo A, Chan S, Friedrichs K, et al.
    Biological markers (BM) with predictive value in metastatic breast cancer (MBC) patients randomly treated with doxorubicin (A) or docetaxel (D).
    Proc Am Soc Clin Oncol 2002;21:213.


  • Dixon M.
    ABC of breast diseases (ed 2), London, BMJ Books, 2000


  • DKG.
    Diagnostik, Therapie und Nachsorge des Mammakarzinoms der Frau. Eine nationale S3-Leitlinie, 2004. www.krebsgesellschaft.de


  • Early Breast Cancer Trialists' Collaborative Group.
    Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet 1998;352:930-942. PM:9752815
    [Medline]


  • Early Breast Cancer Trialists' Collaborative Group.
    Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet 1998;351:1451-1467. PM:9605801
    [Medline]


  • Early Breast Cancer Trialists' Collaborative Group.
    Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet 1996; 348:1189-1196. PM:8898035
    [Medline]


  • Eiermann W, Paepke S, Appfelstaedt J, et al.
    Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.
    Ann Oncol 2001;12:1527-1532. PM:11822750
    [Medline]


  • Ellis MJ, Coop A, Singh B, et al.
    Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
    J Clin Oncol 2001;19:3808-3816. PM:11559718
    [Medline]


  • Ernst DS, Brasher P, Hagen N, et al.
    A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain.
    J Pain Symptom Manage 1997;13:319-26. PM:9204651
    [Medline]


  • Fisher ER, Land SR, Fisher B, et al.
    Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ.
    Cancer 2004;100:238-244. PM:14716756
    [Medline]


  • Fisher B, Costantino JP, Wickerham DL, et al.
    Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
    J Natl Cancer Inst 1998;90:1371-1387. PM:9747868
    [Medline]


  • Fisher B, Anderson S, Wickerham DL, et al.
    Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22.
    J Clin Oncol 1997a;15:1858-1869. PM:9164196
    [Medline]


  • Fisher B, Brown A, Mamounas E, et al.
    Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.
    J Clin Oncol 1997b;15:2483-2493. PM:9215816
    [Medline]


  • Fisher B, Dignam J, Wolmark N, et al.
    Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
    J Natl Cancer Inst 1997c;89:1673-1682. PM:9390536
    [Medline]


  • Fountzilas G, Papadimitriou C, Dafni U, et al.
    Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group.
    J Clin Oncol 2001;19:2232-2239. PM:11304776
    [Medline]


  • Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C.
    The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials.
    Pain 1998;78:157-169. PM:9870569
    [Medline]


  • French Adjuvant Study Group.
    Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial.
    J Clin Oncol 2001;19:602-611. PM:11157009
    [Medline]


  • Gebauer G, Fehm T, Merkle E, et al.
    Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up.
    J Clin Oncol 2001;19:3669-3674. PM:11504748
    [Medline]


  • Ghersi D, Wilcken N, Simes J, et al.
    Taxane containing regimens for metastatic breast cancer.
    Cochrane Database Syst Rev CD003366 2003. PM:15846659
    [Medline]


  • Giordano SH, Buzdar AU, Smith TL, et al.
    Is breast cancer survival improving?
    Cancer 2004;100:44-52. PM:14692023
    [Medline]


  • Giordano SH, Buzdar AU, Kau SW, Hortobagyi GN.
    Improvement in breast cancer survival: results from M. D. Anderson cancer center protocols from 1975-2000.
    Proc Am Soc Clin Oncol 2002;212.


  • Goldhirsch A, Wood WC, Gelber RD, et al.
    Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer.
    J Clin Oncol 2003;21:3357-3365. PM:12847142
    [Medline]


  • Goss PE, Ingle JN, Martino S, et al.
    A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
    N Engl J Med 2003;349:1793-1802. PM:14551341
    [Medline]


  • Green MC, Buzdar AU, Smith T, et al.
    Weekly (wkly) paclitaxel (P) followed by FAC as primary systemic chemotherapy (PSC) of operable breast cancer improves pathologic complete remission (pCR) rates when compared to every 3-week (Q 3 wk) P therapy (tx) followed by FAC- final results of a prospective phase III randomized trial.
    Proc Am Soc Clin Oncol 2002;135. PM:16087943
    [Medline]


  • Greenberg P, Hortobagyi G, Smith T, et al.
    Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.
    J Clin Oncol 1996;14:2197-205. PM:8708708
    [Medline]


  • Guise TA.
    Molecular mechanisms of osteolytic bone metastases.
    Cancer 2000;88:2892-2898. PM:10898330
    [Medline]


  • Hayes DF.
    Atlas of breast cancer (ed 2), Barcelona, Mosby International Ltd., 2000


  • Healy B.
    BRCA genes - bookmaking, fortunetelling, and medical care.
    N Engl J Med 1997;336:1448-1449. PM:9145684
    [Medline]


  • Henderson IC, Berry DA, Demetri GD, et al.
    Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
    J Clin Oncol 2003;21:976-983. PM:12637460
    [Medline]


  • Heuch I, Jacobsen BK, Kvale G.
    Breast cancer and breastfeeding.
    Lancet 2003;361:176. PM:12531603
    [Medline]


  • Hortobagyi GN, Theriault R, Lipton A, et al.
    Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.
    J Clin Oncol 1998;16:2038-2044. PM:9626201
    [Medline]


  • Hortobagyi GN, Porter L, Blayney D, et al.
    Reduction of skeletal related complications in breast cancer patients with osteolytic bone metastases receiving chemotherapy (CT), by monthly pamidronate sodium (PAM) (AREDIA) infusion (Meeting abstract).
    Proc Am Soc Clin Oncol 1996;99.


  • Hortobagyi GN, Frye D, Buzdar AU, et al.
    Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma.
    Cancer 1989;63:37-45. PM:2910423
    [Medline]


  • Howell A, Robertson JF, Abram P, et al.
    Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.
    J Clin Oncol 2004; 22:1605-1613.PM:15117982
    [Medline]


  • Howell A, Osborne CK, Morris C, et al.
    ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen.
    Cancer 2000;89:817-825. PM:10951345
    [Medline]


  • Hui YF, Reitz J.
    Gemcitabine: a cytidine analogue active against solid tumors.
    Am J Health Syst Pharm 1997;54:162-170. PM:9117804
    [Medline]


  • Hutcheon AW, Heys SD, Sarkar TK, et al.
    Docetaxel primary chemotherapy in breast cancer: a five year update of the Aberdeen trial.
    SABCS 2003


  • Jakesz R, Hausmaninger H, Kubista E, et al.
    Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer - Austri-an Breast and Colorectal Cancer Study Group Trial 5.
    J Clin Oncol 2002;20:4621-4627. PM:12488405
    [Medline]


  • Janicke F, Prechtl A, Thomssen C, et al.
    Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
    J Natl Cancer Inst 2001;93:913-920. PM:11416112
    [Medline]


  • Joensuu H, Isola J, Lundin M, et al.
    Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
    Clin Cancer Res 2003;9:923-930. PM:12631589
    [Medline]


  • Jonat W, Kaufmann M, Sauerbrei W, et al.
    Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
    J Clin Oncol 2002;20:4628-4635. PM:12488406
    [Medline]


  • Kato T, Kameoka S, Kimura T, et al.
    The combination of angiogenesis and blood versal invasion as a prognostic indicator in primary cancer.
    Br J Cancer 2003;88:1900-1908. PM:12799634
    [Medline]


  • Klijn JG, Blamey RW, Boccardo F, et al.
    Combined tamoxifen and luteinizing hormo-ne-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
    J Clin Oncol 2001;19:343-353. PM:11208825
    [Medline]


  • Kroman N, Jensen MB, Wohlfahrt J, et al.
    Factors influencing the effect of age on prognosis in breast cancer: population based study - Commentary: much still to learn about relations between tumour biology, prognosis, and treatment outcome in early breast cancer.
    BMJ 2000;320:474-479. PM:10678859
    [Medline]


  • Le Marchand L.
    Cancer preventive effects of flavonoids - a review.
    Biomed Pharmacother 2002;56:296-301. PM:12224601
    [Medline]


  • Levi F, Lucchini F, Negri E, La Vecchia C.
    The fall in breast cancer mortality in Europe.
    Eur J Cancer 2001;37:1409-1412. PM:11435073
    [Medline]


  • Levine MN, Bramwell VH, Pritchard KI, et al.
    Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
    J Clin Oncol 1998;16:2651-2658. PM:9704715
    [Medline]


  • Lombardi P.
    Exemestane, a new steroidal aromatase inhibitor of clinical relevance.
    Biochim Biophys Acta 2002;1587:326-337. PM:12084475
    [Medline]


  • Lonning PE, Taylor PD, Anker G, et al.
    Highdose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy.
    Breast Cancer Res Treat 2001;67:111-116. PM:11519859
    [Medline]


  • Loprinzi CL, Thome SD.
    Understanding the utility of adjuvant systemic therapy for primary breast cancer.
    J Clin Oncol 2001;19:972-979. PM:11181659
    [Medline]


  • Major P, Lortholary A, Hon J, et al.
    Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.
    J Clin Oncol 2001;19:558-567. PM:11208851
    [Medline]


  • Moliterni A, Menard S, Valagussa P, et al.
    HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer.
    J Clin Oncol 2003;21:458-462. PM:12560435
    [Medline]


  • Mouridsen H, Gershanovich M, Sun Y, et al.
    Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.
    J Clin Oncol 2003;21:2101-2109. PM:12775735
    [Medline]


  • Namer M.
    New directions in hormone therapy for metastatic breast cancer.
    Ann Oncol 2002;13:69-72. PM:12401669
    [Medline]


  • Osborne CK, Zhao H, Fuqua SA.
    Selective estrogen receptor modulators: structure, function, and clinical use.
    J Clin Oncol 2000;18:3172-3186. PM:10963646
    [Medline]


  • O'Shaughnessy J, Nag S, Calderillo-Ruiz G, et al.
    Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): Interim results of a global phase III study.
    Proc Am Soc Clin Oncol 2003;22:7.


  • O'Shaughnessy J.
    Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial.
    Oncology (Huntingt) 2002;16:17-22. PM:12435175
    [Medline]


  • Paridaens R, Biganzoli L, Bruning P, et al.
    Paclitaxel versus doxorubicin as first-line singleagent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.
    J Clin Oncol 2000;18:724-733. PM:10673513
    [Medline]


  • Perez-Manga G, Lluch A, Alba E, et al.
    Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial.
    J Clin Oncol 2000;18:2545-2552. PM:10893285
    [Medline]


  • Perry MC.
    Chemotherapeutic agents and hepatotoxicity.
    Semin Oncol 1992;19:551-565. PM:1411653
    [Medline]


  • Peto R, Boreham J, Clarke M, Davies C, Beral V.
    UK and USA breast cancer deaths down 25 % in year 2000 at ages 20-69 years. Lancet 2000;355:1822. PM:10832853
    [Medline]


  • Piccart MJ, Di Leo A, Beauduin M, et al.
    Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.
    J Clin Oncol 2001;19:3103-3110. PM:11408507
    [Medline]


  • Poikonen P, Saarto T, Elomaa I, et al.
    Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal nodepositive breast cancer patients.
    Eur J Cancer 2000;36:43-48. PM:10741293
    [Medline]


  • Possinger K, Wilmanns W.
    [Palliative therapeutic control of tumor progression in patients with metastatic breast cancer].
    Internist (Berl) 1993;34:340-350. PM:7683634
    [Medline]


  • Powles T, Paterson S, Kanis JA, et al.
    Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer.
    J Clin Oncol 2002;20:3219-3224. PM:12149294
    [Medline]


  • Powles T, Eeles R, Ashley S, et al.
    Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial.
    Lancet 1998;352:98-101. PM:9672274
    [Medline]


  • Purushotham AD.
    The diagnosis and management of pre-invasive breast disease: problems associated with management of preinvasive lesions.
    Breast Cancer Res 2003;5:309-312. PM:14580248
    [Medline]


  • Ragaz J, Jackson SM, Le N, et al.
    Adjuvant radiotherapy and chemotherapy in node-posi-tive premenopausal women with breast cancer.
    N Engl J Med 1997;337:956-962. PM:9309100
    [Medline]


  • Robertson JF, Osborne CK, Howell A, et al.
    Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
    Cancer 2003;98:229-238. PM:12872340
    [Medline]


  • Robertson JF, Nicholson RI, Bundred NJ, et al.
    Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluo-ropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.
    Cancer Res 2001;61:6739-6746. PM:11559545
    [Medline]


  • Rodenhuis S, Bontenbal M, Beex LV, et al.
    Highdose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.
    N Engl J Med 2003;349:7-16.


  • Rosen LS, Gordon DH, Dugan W Jr., et al.
    Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.
    Cancer 2004;100:36-43. PM:14692022
    [Medline]


  • Rosen LS, Gordon DH, Dugan W Jr., et al.
    Zoledronic acid (4 mg) is more effective than pamidronate (90 mg) for treating bone metastases in breast cancer patients with at least one osteolytic lesion.
    Annals of Oncology 2002;13:171. PM:11693896
    [Medline]


  • Saarto T, Blomqvist C, Virkkunen P, Elomaa I.
    Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial.
    J Clin Oncol 2001;19:10-17.


  • Schmid M, Jakesz R, Samonigg H, et al.
    Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.
    J Clin Oncol 2003;21:984-990. PM:12637461
    [Medline]


  • Schmid P, Akrivakis K, Flath B, et al.
    Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer.
    Anticancer drugs 1999;10:625-631. PM:10507311
    [Medline]


  • Schmoll HJ, Höffken K, Possinger K.
    Kompendium internistische Onkologie.
    Berlin, Heidelberg, New York, Springer, 1999


  • Schoppmann SF, Bayer G, Aumayr K, et al.
    Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer.
    Ann Surg 2004;240:306-312. PM:15273556
    [Medline]


  • Shannon C, Smith I.
    Is there still a role for neoadjuvant therapy in breast cancer?
    Crit Rev Oncol Hematol 2003;45:77-90. PM:12482573
    [Medline]


  • Shou J, Massarweh S, Osborne CK, et al.
    Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
    J Natl Cancer Inst 2004;96:926-935. PM:15199112
    [Medline]


  • Silverstein MJ, Buchanan C.
    Ductal carcinoma in situ: USC/Van Nuys Prognostic Index and the impact of margin status.
    Breast 2003;12:457-471. PM:14659122
    [Medline]


  • Singletary SE, Allred C, Ashley P, et al.
    Revision of the American Joint Committee on Cancer staging system for breast cancer.
    J Clin Oncol 2002;20:3628-3636. PM:12202663
    [Medline]


  • Sinn HP, Schmid H, Junkermann H, et al.
    [Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy].
    Geburtshilfe Frauenheilkd 1994;54:552-558. PM:8001751
    [Medline]


  • Slamon DJ, Leyland-Jones B, Shak S, et al.
    Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
    N Engl J Med 2001;344:783-792. PM:11248153
    [Medline]


  • Smith I, Dowsett M.
    Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial.
    SABCS 2003


  • Taylor SGt, Gelman RS, Falkson G, Cummings FJ.
    Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women.
    Ann Intern Med 1986;104:455-461. PM:3513684
    [Medline]


  • Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al.
    Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a doseintensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study.
    J Clin Oncol 2003;21:843-850. PM:12610183
    [Medline]


  • Theriault RL, Lipton A, Hortobagyi GN, et al.
    Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebocontrolled trial.
    J Clin Oncol 1999;17:846-854. PM:10071275
    [Medline]


  • Ueno NT, Buzdar AU, Singletary SE, et al.
    Com-bined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center.
    Cancer Chemother Pharmacol 1997;40:321-329. PM:9225950
    [Medline]


  • Untch M, Konecny G, Ditsch N, et al.
    Dosedense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: results of a randomised AGO study.
    Proc Am Soc Clin Oncol 2002;133.


  • van Holten-Verzantvoort AT, Zwinderman AH, Aaronson NK, et al.
    The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer.
    Eur J Cancer 1991;27:544-549. PM:1675865
    [Medline]


  • Veronesi U, Maisonneuve P, Sacchini V, et al.
    Tamoxifen for breast cancer among hysterectomised women.
    Lancet 2002;359:1122-1124. PM:11943263
    [Medline]


Bei ONKODIN publiziert in Kooperation mit "Deutscher Ärzte-Verlag"; Publikation als Buch: Deutscher Ärzte-Verlag  Deutscher Ärzte-Verlag
[Mehr]
Aktuelle Berichte vom 58th
ASH Annual Meeting 2016,
San Diego, Kalifornien, USA [Mehr]
2016 ASCO Annual Meeting - aktuelle Berichte. Dieser Service wird gefördert durch:
mehr 
[Mehr]